Profile data is unavailable for this security.
About the company
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates through two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers packaging, containment solutions, and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
- Revenue in USD (TTM)2.93bn
- Net income in USD568.70m
- Incorporated1923
- Employees10.60k
- LocationWest Pharmaceutical Services Inc530 Herman O. West DriveEXTON 19341United StatesUSA
- Phone+1 (610) 594-2900
- Fax+1 (800) 345-9800
- Websitehttps://www.westpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Insulet Corp | 1.78bn | 234.00m | 14.04bn | 3.00k | 62.40 | 17.75 | 45.52 | 7.88 | 3.21 | 3.21 | 23.61 | 11.29 | 0.7249 | 1.36 | 6.62 | 593,566.70 | 9.53 | 2.71 | 11.42 | 3.14 | 68.86 | 65.81 | 13.14 | 4.28 | 2.75 | 65.58 | 0.6393 | 0.00 | 30.02 | 24.66 | 4,384.78 | 128.77 | -7.63 | -- |
| Hologic Inc | 3.96bn | 466.50m | 16.75bn | 6.99k | 36.93 | 3.46 | 21.33 | 4.23 | 1.94 | 1.94 | 16.30 | 20.76 | 0.4361 | 2.66 | 5.82 | 566,609.40 | 5.14 | 11.40 | 5.74 | 13.38 | 55.12 | 60.29 | 11.78 | 20.95 | 3.29 | -- | 0.3465 | 0.00 | -17.12 | 4.61 | -64.98 | -- | 7.30 | -- |
| Baxter International Inc | 14.89bn | -38.00m | 17.21bn | 60.00k | -- | 2.11 | 13.78 | 1.16 | -0.0762 | 5.21 | 29.33 | 16.04 | 0.5311 | 3.21 | 5.71 | 248,200.00 | -0.107 | 0.1942 | -0.1338 | 0.2333 | 36.31 | 38.20 | -0.2015 | 0.3674 | 1.01 | 3.58 | 0.625 | 1,398.94 | 2.12 | 5.94 | 97.15 | -- | 0.982 | 9.71 |
| Cooper Companies Inc | 3.73bn | 339.90m | 18.61bn | 15.00k | 67.59 | 2.38 | 25.77 | 4.99 | 1.38 | 1.38 | 10.69 | 39.19 | 0.3164 | 1.71 | 5.95 | 248,766.70 | 2.88 | 10.06 | 3.13 | 11.34 | 66.23 | 65.54 | 9.11 | 29.00 | 1.14 | 4.98 | 0.258 | 0.3469 | 8.61 | 7.24 | -23.74 | -3.66 | 15.18 | 31.95 |
| Align Technology, Inc. | 3.92bn | 462.28m | 19.27bn | 21.61k | 42.17 | 5.13 | 32.02 | 4.92 | 6.07 | 6.07 | 51.44 | 49.94 | 0.6497 | 3.96 | 4.27 | 181,237.60 | 7.67 | 16.34 | 11.51 | 24.14 | 70.06 | 71.72 | 11.80 | 23.16 | 1.09 | -- | 0.00 | 0.00 | 3.42 | 14.45 | 23.09 | 2.15 | -4.46 | -- |
| Steris PLC | 5.14bn | 551.44m | 21.59bn | 18.18k | 39.26 | 3.43 | 19.30 | 4.20 | 5.56 | 3.81 | 51.79 | 63.73 | 0.4696 | 4.26 | 5.31 | 282,672.40 | 5.06 | 5.19 | 5.51 | 5.68 | 43.17 | 43.64 | 10.77 | 10.97 | 2.36 | 6.75 | 0.3367 | 36.56 | 13.28 | 13.06 | -1.07 | 12.67 | 13.69 | 8.83 |
| Zimmer Biomet Holdings Inc | 7.45bn | 963.80m | 22.05bn | 18.00k | 23.20 | 1.75 | 11.46 | 2.96 | 4.62 | 4.62 | 35.72 | 61.24 | 0.3491 | 0.9052 | 5.27 | 414,027.80 | 4.52 | 2.21 | 5.14 | 2.52 | 71.89 | 71.25 | 12.95 | 7.28 | 0.802 | 7.32 | 0.315 | 38.90 | 6.55 | -1.40 | 252.86 | -- | 9.44 | 0.00 |
| West Pharmaceutical Services Inc. | 2.93bn | 568.70m | 24.27bn | 10.60k | 43.94 | 9.08 | 34.99 | 8.29 | 7.58 | 7.58 | 39.09 | 36.72 | 0.7995 | 4.20 | 5.65 | 276,283.00 | 15.08 | 15.61 | 17.99 | 18.65 | 37.15 | 38.06 | 18.86 | 18.47 | 1.95 | -- | 0.0714 | 10.69 | 2.18 | 11.43 | 2.28 | 23.76 | 28.16 | 6.20 |
| Resmed Inc | 4.58bn | 958.38m | 31.10bn | 10.14k | 32.59 | 6.72 | 27.32 | 6.79 | 6.50 | 6.50 | 31.07 | 31.52 | 0.6777 | 2.20 | 5.99 | 452,086.70 | 14.17 | 13.59 | 15.98 | 15.89 | 55.78 | 56.98 | 20.91 | 19.22 | 1.97 | 25.88 | 0.1786 | 36.66 | 18.02 | 12.53 | 15.15 | 14.63 | 13.40 | 4.68 |
| GE HealthCare Technologies Inc | 19.50bn | 1.57bn | 34.92bn | 51.00k | 22.27 | 4.71 | 15.70 | 1.79 | 3.43 | 3.43 | 42.54 | 16.24 | 0.6013 | 5.45 | 4.51 | 382,254.90 | 5.01 | -- | 6.86 | -- | 40.69 | -- | 8.33 | -- | 0.8335 | 5.27 | 0.5491 | -- | 6.60 | -- | -26.82 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 8.62m | 11.83% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.23m | 5.81% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.22m | 4.42% |
| Walter Scott & Partners Ltd.as of 31 Mar 2024 | 2.77m | 3.81% |
| Franklin Advisers, Inc.as of 31 Mar 2024 | 2.44m | 3.36% |
| APG Asset Management NVas of 31 Mar 2024 | 2.34m | 3.21% |
| Artisan Partners LPas of 31 Mar 2024 | 2.07m | 2.84% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 1.93m | 2.65% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.72m | 2.36% |
| Brown Advisory LLCas of 31 Mar 2024 | 1.58m | 2.17% |
